Protagenic's Losses Mount Amid Restructuring, Cash Influx

TL;DR

**PTIXW is bleeding cash with a $5.9M loss, but a $4.3M capital raise and aggressive restructuring might buy them time, though the going concern risk is real.**

AI Summary

Protagenic Therapeutics, Inc. (PTIXW) reported a significant increase in net loss for the six months ended September 30, 2025, reaching $5,927,019, a substantial rise from $906,742 in the prior year. This was driven by a surge in total operating expenses to $3,458,276 from $677,205, including a write-off of receivables totaling $1,136,038 and increased research and development expenses of $667,341. The company's cash position improved dramatically to $2,722,451 as of September 30, 2025, up from $14,531 on March 31, 2025, primarily due to $4.3 million raised from warrant exercises and a capital raise. However, Protagenic faces a working capital deficit of $6,845,200 and an accumulated deficit of $11,324,625, raising substantial doubt about its ability to continue as a going concern. A focused restructuring plan, approved on August 8, 2025, aims to reduce annualized operating expenses by approximately $8 million by transitioning to a virtual operating model and suspending preclinical program expenditures.

Why It Matters

Protagenic's substantial net loss of $5.9 million and a working capital deficit of $6.8 million signal significant financial distress, raising red flags for investors regarding long-term viability. The company's strategic shift to a virtual operating model and suspension of preclinical programs, while aiming for an $8 million reduction in annualized operating expenses, indicates a desperate attempt to conserve cash in a highly competitive biopharmaceutical landscape. This could impact employee morale and job security, while customers and the broader market may see delays in new therapeutic developments. Competitors in the stress-related neuropsychiatric and mood disorders space, such as Sage Therapeutics or Axsome Therapeutics, may gain market share as Protagenic re-evaluates its pipeline.

Risk Assessment

Risk Level: high — The company reported an accumulated deficit of $11,324,625 and a working capital deficit of $6,845,200 as of September 30, 2025. These factors, coupled with recurring losses and negative cash flows from operations, raise substantial doubt about Protagenic's ability to continue as a going concern, as explicitly stated in Note 2 of the filing.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment due to the significant going concern risk and mounting losses. Monitor the implementation and effectiveness of the restructuring plan and any future financing activities closely, as the company needs to secure additional funding by March 31, 2026, to avoid further financial distress.

Financial Highlights

debt To Equity

N/A

revenue

N/A

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$5,927,019

eps

N/A

gross Margin

N/A

cash Position

$2,722,451

revenue Growth

N/A

Key Numbers

• $5.93M — Net Loss (Increased from $0.91M year-over-year for the six months ended September 30, 2025, indicating worsening financial performance.)
• $11.32M — Accumulated Deficit (As of September 30, 2025, highlighting significant historical losses and a going concern risk.)
• $6.85M — Working Capital Deficit (As of September 30, 2025, indicating a severe liquidity challenge.)
• $2.72M — Cash in Bank (Increased significantly from $14,531 on March 31, 2025, due to recent financing activities.)
• $4.3M — Capital Raised (From warrant exercises and a capital raise during the six months ended September 30, 2025, providing a temporary cash infusion.)
• $8M — Annualized Expense Reduction (Expected from the restructuring plan, crucial for improving future financial health.)
• 1,934,878 — Common Shares Outstanding (As of November 26, 2025, after a 1-for-14 reverse stock split on May 5, 2025.)
• $1,136,038 — Write off of receivables (A new operating expense for the six months ended September 30, 2025, contributing to the increased loss.)

Key Players & Entities

• Protagenic Therapeutics, Inc. (company) — registrant
• Alterola Biotech, Inc. (company) — merger partner
• Phytanix Bio, Inc. (company) — acquired subsidiary
• ABTI Pharma Limited (company) — subsidiary of Phytanix Bio
• Colin Stott (person) — Seller's Representative in Exchange Agreement
• $5,927,019 (dollar_amount) — net loss for six months ended September 30, 2025
• $11,324,625 (dollar_amount) — accumulated deficit as of September 30, 2025
• $6,845,200 (dollar_amount) — working capital deficit as of September 30, 2025
• $4.3 million (dollar_amount) — capital raised from warrant exercises and ATM during six months ended September 30, 2025
• $8 million (dollar_amount) — expected annualized operating expense reduction from restructuring plan

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company has a significant accumulated deficit of $11,324,625 and a working capital deficit of $6,845,200 as of September 30, 2025. This, coupled with a substantial increase in net loss to $5,927,019 for the six months ended September 30, 2025, raises substantial doubt about its ability to continue as a going concern.
• Restructuring and Program Suspension [medium — operational]: Protagenic has approved a restructuring plan to reduce annualized operating expenses by approximately $8 million. This involves transitioning to a virtual operating model and suspending preclinical program expenditures, indicating a significant shift in operational strategy and potential de-prioritization of certain research efforts.
• Increased Operating Expenses [medium — financial]: Total operating expenses surged to $3,458,276 for the six months ended September 30, 2025, from $677,205 in the prior year. This increase was driven by a $1,136,038 write-off of receivables and higher research and development expenses of $667,341.
• Dependence on Financing [medium — financial]: The company's improved cash position of $2,722,451 as of September 30, 2025, is largely attributable to $4.3 million raised from warrant exercises and a capital raise. This highlights a continued reliance on external financing to fund operations.
• Clinical Trial and Regulatory Approval Risks [high — regulatory]: As a biotechnology company, Protagenic is subject to extensive regulatory review and approval processes for its therapeutic candidates. Delays or failures in clinical trials or regulatory submissions can significantly impact the company's ability to bring products to market and generate revenue.

Industry Context

Protagenic Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing novel therapeutics. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success often depends on scientific innovation, effective clinical trial execution, and securing substantial funding to advance drug candidates through development stages.

Regulatory Implications

As a clinical-stage biotechnology company, Protagenic is subject to rigorous oversight by regulatory bodies like the FDA. Any delays in clinical trials, adverse findings, or failures to meet regulatory standards can severely impact development timelines and the potential for commercialization, posing significant risks to the company's future.

What Investors Should Do

1. Monitor Restructuring Success
2. Evaluate Future Financing Needs
3. Track R&D Pipeline Progress
4. Assess Management's Execution Capability

Key Dates

• 2025-09-30: Six months ended September 30, 2025 — Reported a net loss of $5,927,019 and a working capital deficit of $6,845,200, with cash position improving to $2,722,451 due to financing.
• 2025-08-08: Restructuring Plan Approved — Aimed at reducing annualized operating expenses by approximately $8 million through a virtual operating model and suspension of preclinical programs.
• 2025-05-05: 1-for-14 Reverse Stock Split — Reduced the number of common shares outstanding to 1,934,878 as of November 26, 2025, likely to meet exchange listing requirements or improve per-share metrics.
• 2025-03-31: March 31, 2025 — Cash balance was $14,531, indicating a critical need for the subsequent financing activities.

Glossary

Accumulated Deficit

The total net losses of a company since its inception that have not been offset by net income. (Indicates the company's historical unprofitability and contributes to the going concern risk.)

Working Capital Deficit

Occurs when a company's current liabilities exceed its current assets, indicating a short-term liquidity challenge. (Highlights Protagenic's immediate difficulty in meeting its short-term obligations.)

Going Concern

An assumption that a company will continue to operate for the foreseeable future, typically at least 12 months. (Substantial doubt about this means the company may not be able to meet its obligations as they come due.)

Warrant Exercises

The act of a holder of a warrant converting it into shares of stock, typically by paying an exercise price. (A source of capital infusion for the company, as seen with the $4.3 million raised.)

Reverse Stock Split

A corporate action to reduce the number of outstanding shares of stock by consolidating existing shares into fewer, proportionally more valuable shares. (Protagenic executed a 1-for-14 reverse split, impacting share count and potentially stock price perception.)

Write-off of Receivables

An accounting entry that removes an uncollectible debt from accounts receivable, recognizing it as a bad debt expense. (Contributed $1,136,038 to the increased operating expenses and net loss for the period.)

Year-Over-Year Comparison

The six months ended September 30, 2025, show a dramatic deterioration in net loss, increasing to $5,927,019 from $906,742 in the prior year, primarily due to a surge in operating expenses, including a significant write-off of receivables. While the cash position has improved substantially to $2,722,451 from $14,531 due to recent financing, the company faces a severe working capital deficit of $6,845,200 and an accumulated deficit of $11,324,625, intensifying going concern risks compared to the prior period.

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 PTIX Nasdaq Capital Market Commo

Filing Documents

• form10-q.htm (10-Q) — 1098KB
• ex31-1.htm (EX-31.1) — 19KB
• ex31-2.htm (EX-31.2) — 19KB
• ex32-1.htm (EX-32.1) — 10KB
• 0001493152-25-025201.txt ( ) — 5378KB
• ptix-20250930.xsd (EX-101.SCH) — 41KB
• ptix-20250930_cal.xml (EX-101.CAL) — 55KB
• ptix-20250930_def.xml (EX-101.DEF) — 196KB
• ptix-20250930_lab.xml (EX-101.LAB) — 337KB
• ptix-20250930_pre.xml (EX-101.PRE) — 271KB
• form10-q_htm.xml (XML) — 742KB

Financial Statements

Financial Statements: Consolidated Balance Sheets at September 30, 2025 (unaudited) and March 31, 2025 (audited) 3 Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended September 30, 2025 and 2024 (unaudited) 4 Consolidated Statements of Changes in Stockholders' Equity for the three and six months ended September 30, 2025 and 2024 (unaudited) 5 Consolidated Statements of Cash Flows for the six months ended September 30, 2025 and 2024 (unaudited) 6

Notes to Consolidated Financial Statements (unaudited)

Notes to Consolidated Financial Statements (unaudited) 7 Item 2

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 26 Item 3

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 33 Item 4

Controls and Procedures

Controls and Procedures 33 Part II. Other Information Item 1

Legal Proceedings

Legal Proceedings 34 Item 1A

Risk Factors

Risk Factors 34 Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 34 Item 3 Defaults upon Senior Securities 34 Item 4 Mine Safety Disclosures 35 Item 5 Other Information 35 Item 6 Exhibits 35

Signatures

Signatures 36 2 PART I - FINANCIAL INFORMATION Item 1. Financial Statements PROTAGENIC THERAPEUTICS, INC., AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS September 30, 2025 March 31, 2025 (Unaudited) (Audited) ASSETS Current assets: Cash in bank $ 2,722,451 $ 14,531 Prepaid expenses 90,643 - VAT receivable 44,043 73,524 Inventories 1,075 1,038 Total current assets 2,858,212 89,093 Long-term assets: Fixed assets, net 51,407 - Intangible assets, net 2,093,228 - Total long-term assets 2,144,635 - Total Assets $ 5,002,847 $ 89,093 LIABILITIES AND STOCKHOLDERS' DEFICIT LIABILITIES: Current liabilities: Notes payable, net $ 3,156,052 $ 1,669,921 Accounts payable 1,641,443 961,117 Accrued liabilities 407,975 249,063 Derivative liabilities 3,656,394 1,382,750 Loans payable, related parties 841,548 779,201 Total current liabilities 9,703,412 5,042,052 Total liabilities 9,703,412 5,042,052 Commitments and Contingencies - - STOCKHOLDERS' DEFICIT: Preferred stock, $ 0.000001 par value. 20,000,000 shares authorized none issued and outstanding - - Preferred stock, $ 0.000001 par value. 2,000,000 shares authorized none issued and outstanding - - Series B Convertible Preferred stock, $ 0.000001 par value. 18,000,000 shares authorized 0 and 17,000 shares issued and outstanding - - Series C Convertible Preferred stock, $ 0.000001 par value. 15,000 shares authorized 5,705 and 0 issued and outstanding - - Series C-1 Convertible Preferred stock, $ 0.000001 par value. 1,000,000 shares authorized 950,000 and 0 issued and outstanding 1 - Series D Convertible Preferred stock, $ 0.000001 par value. 20,000 shares authorized 20,000 and 0 issued and outstanding - - Preferred stock, value - - Common stock, $ 0.0001 par value, respectively; 100,000,000 authorized; 1,934,878 and 5,800,000 shares issued outstanding 195 - Additional paid in capital 6,845,036 455,657

View Full Filing

View this 10-Q filing on SEC EDGAR